Page 5 - KIDNEY CANCER

Background

• Multiple studies point to the MET proto-

oncogene as a potential driver of pRCC 1-3

• Although more common in type I versus

type II pRCC, MET mutation and copy

number alteration occur in a large

proportion of both subtypes

• Aim to determine if MET inhibitors could

improve clinical outcome relative to

sunitinib in patients with metastatic pRCC

2
1 Cancer Genome Atlas Research Network et al N Engl J Med 2016; 374: 135–45; Pal SK et al Eur Urol 2018; 73: 71–8; Albiges, L et al Clin Cancer Res 2014; 20:3411–21.
Figure Source: Fay A et al Clin Cancer Res 2014; 20: 3361–63